ArticleOncology letters2025
Dynamic changes in tumor blood flow during chemotherapy: Implications in customized treatment for pancreatic cancer.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual-energy CT extracellular volume fraction for predicting the chemotherapeutic response in pancreatic ductal adenocarcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal malignancy, and the optimal selection of neoadjuvant chemotherapy (NAC) remains a critical clinical challenge. Tumor blood flow (TBF) is associated with chemotherapeutic response. However, the role of TBF in regimen-specific outcomes remains unclear. Thus, this association was investigated in the present study. A total of 58 patients with PDAC who underwent pancreatectomy after NAC between 2011 and 2023 were retrospectively analyzed. TBF was quantified using contrast-enhanced computed tomography. Patients were stratified into high and low pre-treatment TBF groups, and the associations between TBF, chemotherapy regimen [gemcitabine plus S-1 (GS), gemcitabine plus nab-paclitaxel (GnP) and modified FOLFIRINOX (mFOLFIRINOX)] and therapeutic pathological response were evaluated. Changes in TBF after treatment and intra-tumoral vascular characteristics were also assessed. A total of 35 (60.3%) and 23 (39.7%) patients were categorized into the low and high TBF groups, respectively. The prevalence of a therapeutic pathological response of at least grade II was greater in the high TBF group (P=0.027). A higher pre-treatment TBF was associated with an improved therapeutic pathological response in patients receiving mFOLFIRINOX (P=0.010) but not in those receiving GnP or GS. In patients with low pre-treatment TBF, GnP therapy increased TBF post-treatment (P=0.004), whereas mFOLFIRINOX and GS did not. Furthermore, post-treatment TBF was correlated with the number of intra-tumoral patent vessels (r=0.486; P<0.001). In conclusion, TBF may serve as a predictive biomarker for selecting neoadjuvant chemotherapy regimens for PDAC. High pre-treatment TBF was associated with improved efficacy of mFOLFIRINOX, whereas GnP may be beneficial for tumors with initially low TBF by improving tumor perfusion during therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.